Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

TRX-818 is an anticancer compound.1,2 It inhibits vasculogenic mimicry network formation in C8161 and SK-MEL-28 melanoma cells when used at concentrations ranging from less than or equal to 5 to 10 nM. 1 TRX-818 (10 nM) decreases pro-Nodal protein levels and Smad2 phosphorylation in C8161 cells. It reduces tumor volume with a minimum effective dose (MED) value of 50 mg/kg and decreases the number of vasculogenic mimicry channels in tumors when administered at a dose of 100 mg/kg in an HCT116 colon cancer mouse xenograft model. TRX-818 (7.5, 15, and 30 mg/kg) reduces tumor growth in a Hep3B mouse xenograft model in a dose-dependent manner.2
WARNING This product is not for human or veterinary use.
1. Use of aryl-
2. Design, synthesis, and preclinical evaluation of new 5,6-